(PharmaNewsWire.Com, March 14, 2017 ) The Global Cancer Monoclonal Antibodies was currently estimated to be at a USD 27 billion in 2016 and is poised to reach USD 45 billion by the end of 2021 with a CAGR of 11.2% from 2016 to 2021. Cancer is a severe diseases causing millions of death worldwide every year.
Cancer starts from a single cell and genetically transforms a normal cell in to tumour cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest on monoclonal antibodies. While the drugs are used for the treatment of cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells as well along with cancerous cells. This prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The dramatic increase of the number of cancer patients has led many pharmaceutical players to invest in monoclonal antibodies market. Increasing investment in research and development of genomic studies, technological advancements in genetic sequencing and target gene selection, specificity of monoclonal antibodies to target only the cancer cells with no side effects are the some of the driving forces of the market. Increased prevalence of cancer being the key driver for the Monoclonal Antibodies Market, it is expected to grow lucratively in the next 5 years with the presence of strong products in the pipeline. However, there are few restraints for the growth of the market like high development cost being the major one. And also, stringent regulatory guidelines, long durations required for the research and development of antibodies, longer periods of clinical trials are some of the hurdles faced by the market.
The global Monoclonal Antibodies are segmented bases on the application as Liver, Breast, Blood, Brain, Hodgkins and Non-Hodgkins lymphoma, Colorectal, leukaemia and others. The market is also analysed based on segmention by type of monoclonal antibodies as murine antibodies, chimeric and humanised antibodies and fully humanized antibodies. The market is also segemented by Conjugated Cancer therapies using Monoclonal Antibodies as Immunoliposome, Radioimmunotherapy, ADEPT, immunocytokines and others. The global market is also categorised based on the geographical region as North America, Europe, Asia-Pacific, Middle East & Africa and Latin America.
The highly customizable nature of the monoclonal antibodies are attracting various organizations, research institutes and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, glaxosmithkline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics and Spectrum Pharmaceuticals.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
